Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0585 • ACR Convergence 2021
Predictors of Health-Related Quality of Life in Rheumatoid Arthritis Patients
Nejat Hassen¹, Yufei Zheng², Hui Xie², Karim Khan³, Jacek Kopec⁴ and Diane Lacaille², ¹University of British Columbia, Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada
Background/Purpose: Health-related quality of life (HRQoL) is lower in rheumatoid arthritis (RA) patients compared to the general population, yet a comprehensive study evaluating predictors and…
Abstract Number: 0637 • ACR Convergence 2021
Assessing the Rates of Cervical Cancer Screening in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Tara Skorupa¹, Sonia Khatter², Alana Freifeld¹ and Elena Weinstein³, ¹University of Colorado, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Englewood, CO
Background/Purpose: Prior studies have described increased incidence of cervical dysplasia and cervical cancer in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), suggesting…
Abstract Number: 0791 • ACR Convergence 2021
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
Juan Schmukler¹, Kyle Schroeder² and Theodore Pincus², ¹Mount Sinai Hospital - Rheumatology, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been advanced considerably by biological agents with capacity for stringent control of inflammation. A “treat-to-target” directive toward remission…
Abstract Number: 0807 • ACR Convergence 2021
Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
Zafer Akman¹, Gilles Boire², Nathalie Carrier³, Sophie Roux⁴, Ariel Masetto², Artur deBrum Fernandes⁵, Patrick Liang², Patricia L Dobkin⁶ and Allard-Chamard Hugues⁷, ¹Istanbul University Cerrahpasa, İstanbul, Turkey, ²Universite de Sherbrooke, Sherbrooke, QC, Canada, ³CIUSSS de l'Estrie - CHUS, Sherbrooke, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Universite De Sherbrooke, Fleurimont, QC, Canada, ⁶McGill University, Montréal, QC, Canada, ⁷Universit de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: Patients recently diagnosed with RA employ various coping strategies. We aimed to describe these strategies over time and determine if specific strategies impacted patient…
Abstract Number: 0826 • ACR Convergence 2021
Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19
Miao Wang¹, Sylvie Lardeux², Elisea Avalos-Reyes³, Michele Hamburger⁴ and Kjel Johnson⁵, ¹CVS Health, New York, NY, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴Frances Hamburger Institute, Hauppauge, NY, ⁵CVS Health, Lincoln, RI
Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 0997 • ACR Convergence 2021
Citrullinated Vimentin Induces Epigenetic Memory of the Innate Immune System
Katerina Laskari¹, Shweta Sabu², Oliver Distler³, Emmanuel Karouzakis² and Michel Neidhart², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: During trained immunity, monocytes and macrophages undergo a functional and transcriptional reprogramming toward activation, which is induced by a priming stimulus and results in…
Abstract Number: 1076 • ACR Convergence 2021
Combining Fuzzy Logic with Time-Driven Activity Based Costing Within the Rheumatoid Arthritis Care Cycle: Insights from a Dutch Hospital
Fiona Koster¹, Deirisa Lopes Barreto², Marc Kok³ and Angelique Weel-Koenders¹, ¹Maasstad Hospital Rotterdam, Rotterdam, Netherlands, ²Maasstad Hospital Rotterdam, Rotterdam, ³Maasstad Hospital, Rotterdam, Netherlands
Background/Purpose: Transparency and management of healthcare costs is warranted for rheumatoid arthritis (RA) as the disease places a great economic burden on a patient and…
Abstract Number: 1203 • ACR Convergence 2021
A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Carol Hitchon⁵, Gilles Boire⁶, Diane Tin⁷, Louis Bessette⁸, Edward Keystone⁹, Carter Thorne⁷, Janet Pope¹⁰ and Susan Bartlett³, ¹Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Laval University, Québec City, QC, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: The Clinical Disease Activity Index (CDAI) is a frequently used composite measure by rheumatologists (MD) in routine care used to guide target-based treatment decisions.…
Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
Abstract Number: 1235 • ACR Convergence 2021
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Bruno Fautrel¹, Bochao Jia², Jianmin Wu³, Ju Ji², Julie Birt², Ewa Haladyj² and Tsutomu Takeuchi⁴, ¹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianaplolis, IN, ⁴Div. Rheumatology, Keio University, Tokyo, Japan
Background/Purpose: Fatigue is very common in rheumatoid arthritis (RA) and impairs patient quality of life. Baricitinib (BARI) improved fatigue, pain and other patient-reported outcomes (PROs)…
Abstract Number: 1251 • ACR Convergence 2021
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Borja Hernandez-Breijo¹, Ioannis Parodis², Chamaida Plasencia-Rodríguez³, Mariana Díaz-Almirón⁴, Ana Martínez-Feito⁵, Marta Novella-Navarro³, Dora Pascual-Salcedo¹ and Alejandro Balsa³, ¹Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ³Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: The latest breakthroughs in the pathophysiology of rheumatoid arthritis (RA) highlighted the activation of B cells as a trigger of the joint flare initiation…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 1650 • ACR Convergence 2021
Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
Paolo Massimo Buscema¹, Giulia Massini², Francesca Della Torre², Masoud Asadi-Zeydabadi³, Colin O'Donnell⁴, Francis Newman⁵, Randall Tagg³, Weldon Lodwick⁵, Christopher Collora⁴, Marie Feser⁴, LauraKay Moss⁴, William Robinson⁶, Geoffrey Thiele⁷, Ted Mikuls⁷, Jess Edison⁸, V. Michael Holers⁴ and Kevin Deane⁹, ¹Semeion Research Center of Sciences of Communication; University of Colorado Denver Department of Mathematical and Statistical Sciences, Rome, Italy, ²Semeion Research Center of Sciences of Communication, Rome, Italy, ³University of Colorado Denver Department of Physics, Denver, CO, ⁴University of Colorado Denver, Aurora, CO, ⁵University of Colorado Denver Department of Mathematical and Statistical Sciences, Denver, CO, ⁶Stanford University, Palo Alto, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations of antibodies to citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and…
Abstract Number: 1666 • ACR Convergence 2021
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Patricia Katz¹, Sarah Patterson², Mary Nakamura³, Aric Prather¹, Laura Trupin⁴, Stephanie Rush¹ and Katie Stone¹, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UCSF/SFVAHCS, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA
Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].